Zobrazeno 1 - 9
of 9
pro vyhledávání: '"John P. Middleton"'
Autor:
Linda F. Fried, Jennifer J. Gassman, James C. Carr, Xuan Cai, Tamara Isakova, Brett Larive, Kalani L. Raphael, Joachim H. Ix, Anand Srivastava, Michel Chonchol, Jungwha Lee, John P. Middleton, Pottumarthi V. Prasad, Alfred K. Cheung, Cynthia Kendrick, Dominic S. Raj, Myles Wolf, Wei Li, Geoffrey A. Block, Stuart M. Sprague
Publikováno v:
Clinical Journal of the American Society of Nephrology. 15:776-783
Background and objectives Kidney functional magnetic resonance imaging (MRI) requires further investigation to enhance the noninvasive identification of patients at high risk of CKD progression. Design, setting, participants, & measurements In this e
Autor:
Mohammed Sika, Gerald Schulman, Yu Shyr, Roger A. Rodby, Ernest Han, John P. Middleton, Heidi Chen, Stephen Clyne, Raymond C. Harris, Ruediger W. Lehrich, Marvin Sinsakul, Julia B. Lewis
Publikováno v:
American Journal of Kidney Diseases. 50:946-951
Background Preclinical data suggest that cyclooxygenase 2 inhibitors decrease proteinuria and preserve glomerular structure in animal models of diabetic nephropathy. The objective of this study is to compare the efficacy and safety of celecoxib with
Autor:
Robert A. Phillips, John P. Middleton, Tom Greene, DeAnna Cheek, Akinlou Ojo, Julia B. Lewis, Jackson T. Wright, Mohammed Sika, Lawrence E. Agodoa, Daniel T. O'Connor
Publikováno v:
American Journal of Kidney Diseases. 38:744-753
Renal function measurements were obtained in 1,703 African Americans with presumed hypertensive nephrosclerosis who were screened for entry into the African-American Study of Hypertension and Kidney Disease (AASK). We examined the effect of race on r
Autor:
Han W. Kim, Anna Lisa Crowley, Raymond J. Kim, Faisal Nabi, Miguel A. Quinones, Dipan J. Shah, Cassidy Duran, Lucien Abboud, William A. Zoghbi, Sreekanth Vemulapalli, Igor Klem, John P. Middleton
Publikováno v:
Journal of Cardiovascular Magnetic Resonance, Vol 15, Iss Suppl 1, p P228 (2013)
Journal of Cardiovascular Magnetic Resonance
Journal of Cardiovascular Magnetic Resonance
Background Imaging in patients with renal insufficiency (RI) is limited by contrast induced nephropathy and nephrogenic systemic fibrosis. Ferumoxytol is an FDA approved superparamagnetic iron compound used for the treatment of anemia in patients wit
Autor:
Rebecca K. Proctor, Charles J. Davidson, Deirdre M. Collins, Michael B. Lambert, John P. Middleton, Steve J. Schwab, Glenn E. Newman
Publikováno v:
Kidney International. 41(5):1292-1296
Fistula dysfunction: Effect on rapid hemodialysis. Rapid hemodialysis (Qb 400 to 500ml/min) places considerable demands on hemodialysis vascular access. This six-month prospective study enrolled 52 patients and evaluated urea recirculation as a means
Publikováno v:
American journal of cardiovascular drugs : drugs, devices, and other interventions. 3(3)
Strategies to delay progression of established renal disease have primarily been directed at examining the class of antihypertensive therapy and/or the level of blood pressure control. In diabetic renal disease many trials have noted a protective rol
Autor:
Edgar R. Miller, John P. Middleton, Janice P. Lea, Tom Greene, Michael S. Lipkowitz, George L. Bakris, Winifred Smith, Shaul G. Massry, Stephen G. Rostand, Lee A. Hebert
Publikováno v:
Archives of Internal Medicine. 165:947
The magnitude of proteinuria is associated with a graded increase in the risk of progression to end-stage renal disease and cardiovascular events. The objective of this study was to relate baseline and early changes in proteinuria and glomerular filt
Autor:
Kenneth Jamerson, Robert A. Phillips, Robert D. Toto, Stephen G. Rostand, Lee Hebert, Jeanne Charleston, J. Gassman, Richard J. Glassock, John P. Middleton, Julia B. Lewis, Lawrence J. Appel, Jackson T. Wright, George L. Bakris, De Anna Cheek, Tom Greene, L. Y. Agodoa, Janice G. Douglas-Baltimore
Publikováno v:
JAMA. 288:2421
ContextHypertension is a leading cause of end-stage renal disease (ESRD) in the United States, with no known treatment to prevent progressive declines leading to ESRD.ObjectiveTo compare the effects of 2 levels of blood pressure (BP) control and 3 an
Autor:
S. Massry, C. J. Johnson, J. Gassman, Josephine P. Briggs, W. Cleveland, A. Gabriel, M. Faulkner, Gerald Schulman, L. Hiremath, Glenn Beck, John P. Middleton, Kenneth Jamerson, Keith C. Norris, Tom Greene, Janice G. Douglas, J. Lash, C. C. Tisher, L. Y. Agodoa, Stephen G. Rostand, C. DeAnna, Joel D. Kopple, Lee Hebert, A. Ojo, J. Bourgoignie, M. Lipkowitz, Julia B. Lewis, S. Xu, William Jay Smith, Robert D. Toto, V. Pogue, Mahboob Rahman, Margaret Douglas, J. Kusek, J T Jr Wright, D. Dowie, George L. Bakris, Lawrence J. Appel, Edgar R. Miller, J. Lea, Otelio S. Randall, Denyse Thornley-Brown, Robert A. Phillips, Y. Hall, Daniel T. O'Connor, Jeanne Charleston
Publikováno v:
JAMA. 285:2719
ContextIncidence of end-stage renal disease due to hypertension has increased in recent decades, but the optimal strategy for treatment of hypertension to prevent renal failure is unknown, especially among African Americans.ObjectiveTo compare the ef